07.05.09 18:36 Age: 309 days
Ipsogen launches a new test to guide hormonotherapy prescription in breast cancer
Category: Breast Cancer
The Genomic HR test will help pathologists to identify endocrine-responsive tumors that should benefit from hormonotherapy
IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announces the European launch of the MapQuant Dx™ HR test. Running on an Affymetrix microarray diagnostic platform, this new genomic test will improve the identification of endocrine-responsive tumors by measuring the expression of genes related to oestrogen and progesterone biology in breast cancer.
More
